Wen Wee Ma, MBBS

Assistant Professor

Department of Medicine

Roswell Park Cancer Institute

Profile

Areas of Expertise:

Colon cancer

Liver cancer

Pancreatic cancer

Rectal cancer

Research

Research Interests:

Drug development

Phase I clinical trials (advanced solid tumors)

Background Information

Education and Training:

MBBS - University of Sydney, Sydney, NSW, Australia

Residency:

Johns Hopkins Bayview Medical Center, Baltimore, MD

Board Certification:

Hematology, American Board of Internal Medicine

Internal Medicine, American Board of Internal Medicine

Medical Oncology, American Board of Internal Medicine

Fellowships:

Medical Oncology/ Hematology, Johns Hopkins University, Baltimore, MD

Publications

Publications:

Liu W, Guan M, Su B, Li J, Ma W, Liu C, Li M, Lin Y, Lu Y. Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clinica chimica acta 2010; 411(13-14):940-946
May KS, Javle MM, Gibbs JF, Kuvshinoff BW, Fakih M, Russo RC, Flaherty L, Ma WW, Iyer RV, Wilding GE, Chandrasekhar R, Khushalani NI, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. International journal of radiation oncology, biology, physics 2010; 76(4):1193-1198
Malik NK , Wilding GE , Gibbs JF , Kuvshinoff BW , Iyer RV , Flaherty L , Ma W , May KS , Chandrasekhar R , Yang GY. Chemoradiotherapy vs. chemotherapy alone in patients with locally advanced unresectable pancreatic carcinoma: a 10-year experience. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S311-S312
Yang G , Wilding G , Kuvshinoff B , Ma W , Flaherty L , Watroba N , May KS , Chandrasekhar R , Malik N , Gibbs J. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S298
Adjei AA, Chai F, Savage R, Means JA, Skupien D, Fetterly GJ, Ma W, Dy GK, Sosman JA, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):3024
Calvo E, Millham RD, Denis LJ, Gualberto A, Bahleda R, Soria J, Hidalgo M, Tolcher AW, Ma W, Adjei AA. Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs). Journal of clinical oncology 2010; 28(15 Suppl.):3026
Cohen SJ, Wong L, Lee F, Pascual RA, Modiano M, Ma W, Nugent FW, Conkling P, Zalupski MM, Hersh E. A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naive pancreatic adenocarcinoma (PC). Journal of clinical oncology 2010; 28(15 Suppl.):4076
Ma W, Adjei AA, Wilhelm F, Bellemarre S, Messersmith WA, Ghalib MH, Dy GK, Freas E, Mani S, Jimeno A. Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):e13515
Garrido-Laguna I, Laheru D, Rubio-Viqueira B, Rudek MA, Barrett M, Iacobuzio-Donahue C, Donehower R, Jimeno A, Rajeshkumar NV, Zhao M, Villaroel MC, Ma WW, Angenendt M, Uson M, Tan AC, Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British journal of cancer 2010; 103(5):649-655
Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
Ma WW, Rudek MA, Donehower RC, Pawlik TM, Cameron JL, Wolfgang CL, Messersmith WA, Laheru D, Jimeno A, Herman JM, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Translational oncology 2010; 3(6):373-379
Salerno May K, Chandrasekhar R, Flaherty L, Russo RC, Ma W, Kuvshinoff BW, Gibbs JF, Wilding GE, Yang G. Change in renal function after chemoradiotherapy for pancreatic cancer : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #231
Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA : a cancer journal for clinicians 2009; 59(2):111-137
Ma WW, Pomper MG, Jimeno A, Endres C, Wahl R, Laheru D, Messersmith WA, Vilardell F, Song D, Jacene H, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Journal of clinical oncology 2009; 27(16):2697-2704
Ma WW. Development of focal adhesion kinase inhibitors in cancer therapy. Anti-cancer agents in medicinal chemistry 2011; 11(7):638-642
Borad MJ, Sigal D, Uronis H, Stephenson J, Bahary N, Rarick MU, DeMarco LC, Finnegan TJ, Chiorean EG, Ryan DP, Cohn AL, Ulrich BK, Harish VC, Anderes EN, Ma WW, Yu PP, Sinicrope F, Eng C, Sunkara UK, Reddy SG. Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):TPS176
Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh L, Dubowy RL, Jeffers M, Rajagopalan P, Weekes CD. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3007
Ma WW, Messersmith WA, Dy GK, Freas E, Whitworth A, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3101
Infante J, Bendell J, Dy GK, Ma WW, Novello S, Huff AC, Graham A, Burris H, Ottesen LH, Adjei AA. Phase Ib study of pemetrexed administered in combination with pazopanib (GW786034). Journal of thoracic oncology 2009; 4(9 Suppl. 1):S413
Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Journal of hepatology 2012; 56(1):176-183
Malik NK, May KS, Groman A, Patil S, Gibbs J, Kuvshinoff B, Ma W, Iyer R, Warren G, Yang G. Outcomes and Tolerability of Treatment for Locally Advanced Pancreatic Cancer Patients 65 Years or Older. International journal of radiation oncology, biology, physics 2011; 81(2 Suppl.):S336
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. Journal of clinical oncology 2008; 26(25):4172-4179
Musib L, Eppler S, Choo E, Deng A, Miles D, Hsu B, Rosen L, Sikic B, LoRusso P, Ma W, Goldman J, Fisher G, Weise A, Dy G, Chan I, Ware J. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1304
Pawaskar DK, Straubinger R, Fetterly G, Ma W, Jusko W. Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #27
Rosen L, LoRusso P, Ma WW, Goldman J, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Gates MR, Jones C, Musib L, De Crespigny A, Chan I, Sikic B. A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #4716
Williams S, Fredrickson J, Mckenzie M, Jones C, Gates M, Hoeflich K, LoRusso P, Rosen L, Sikic B, Ma WW, Chan I, de Crespigny AJ. Preclinical and clinical evidence for MEK pathway inhibition by GDC-0973 using FDG-PET. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1280
Zhang H, Tang H, Shao H, Gao C, Hylander BL, Repasky EA, Dy GK, Ma WW, Yu C, Adjei AA. Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumors in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1
Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research 2012; 18(7):2048-2055
Fora AA, McMahon JA, Wilding G, Groman AE, Ma WW, Romano KS, Fakih M. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS-wild type tumors who progressed on prior standard dose cetuximab and irinotecan. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #3582
Jimeno A, Senzer NN, Rudin CM, Ma WW, Halmos B, Schnadig ID, Levy B, Hausman DF, Peterson S, Walker LN. PX-866 and docetaxel in patients with advanced solid tumors. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #3024
Kotowski AS, Yarlagadda N, Salerno MK, Warren GW, Kuvshinoff BW, Wilkinson NW, Tan W, Iyer RV, Ma WW. Single institution experience of chemoradiation with gemcitabine versus capecitabine in borderline resectable and locally advanced pancreatic cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14659
Martell RE, Puzanov I, Ma WW, Santoro A, Dy GK, Goff LW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4117
Means-Powell JA, Adjei AA, Puzanov I, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #8519
Puzanov I, Sosman JA, Santoro A, Martell RE, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Strauss GM, Zucali PA, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4545
Kotowski A, Ma WW. Emerging therapies in pancreas cancer. Journal of gastrointestinal oncology 2011; 2(2):93-103
Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson III AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JDI, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella II P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(6):703-713

Referral

Email:

WenWee.Ma@RoswellPark.org

Fax:

716-845-8232